DYAI - Dyadic International, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.5000
0.0000 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.5000
Open4.4900
Bid4.1200 x 2900
Ask4.7500 x 1300
Day's Range4.3236 - 4.7500
52 Week Range2.5100 - 8.0000
Volume165,497
Avg. Volume265,438
Market Cap122.459M
Beta (5Y Monthly)0.26
PE Ratio (TTM)N/A
EPS (TTM)-0.2640
Earnings DateMar 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
  • ACCESSWIRE

    Dyadic International, Inc. to Present at the New York City based Investor Summit on March 25th-26th

    NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Dyadic International, Inc. (Nasdaq: DYAI) Dyadic's Chief Financial Officer Ping Rawson will be presenting at this year's New York City based Investor Summit ...

  • ACCESSWIRE

    Dyadic Presents New Business Opportunities to Address COVID-19, Influenza and Continued Scientific and Business Development Progress

    JUPITER, FL / ACCESSWIRE / March 18, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its management participated in the ROTH Virtual Conference on Tuesday, March 17, 2020. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales.

  • ACCESSWIRE

    Dyadic to Report Year End 2019 Financial Results on Monday, March 30, 2020

    JUPITER, FL / ACCESSWIRE / March 16, 2020 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for year ended December 31, 2019 after the market close on Monday, March 30, 2020 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales.

  • Dyadic International's (NASDAQ:DYAI) Wonderful 462% Share Price Increase Shows How Capitalism Can Build Wealth
    Simply Wall St.

    Dyadic International's (NASDAQ:DYAI) Wonderful 462% Share Price Increase Shows How Capitalism Can Build Wealth

    Buying shares in the best businesses can build meaningful wealth for you and your family. While the best companies are...

  • Coronavirus update: Trump taps Pence to lead coronavirus response; first case in CA with no travel link
    Yahoo Finance

    Coronavirus update: Trump taps Pence to lead coronavirus response; first case in CA with no travel link

    Europe’s attempts to contain its escalating coronavirus outbreak appeared to be faltering, as Germany became the latest country to warn that it was on the verge of an epidemic.

  • ACCESSWIRE

    Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases

    NES-ZIONA, ISRAEL and JUPITER, FL / ACCESSWIRE / February 25, 2020 / Dyadic International, Inc. (''Dyadic'') (DYAI), a global biotechnology company announced today that they are joining the global fight against the coronavirus outbreak by collaborating with The Israel Institute for Biological Research ("IIBR"), a governmental research institute established to provide the State of Israel with scientific response to chemical and biological threats. IIBR will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies (mAbs) that may help combat the outbreak of the COVID-19 virus (Coronavirus).

  • ACCESSWIRE

    Dyadic Announces New Milestone as G2 Human Like Glycosylation Reached

    JUPITER, FL / ACCESSWIRE / February 24, 2020 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, announced that data presented at the 15th European Conference on Fungal Genetics ("ECFG15") demonstrated that its C1 strain has been glyco-engineered to achieve a core human like G2 glycan level over 76% on Host Cell Proteins (HCP). The G2 glycosylation data was presented by Anne Huuskonen from the VTT Technical Research Centre of Finland Ltd ("VTT") at the ECFG15 conference in Rome, Italy on Wednesday, February 19. "Our collaboration with Dyadic continues to achieve new scientific milestones regarding glycoengineering Dyadic's C1 industrially proven cell line, building upon the 95% core human G0 glycosylation milestone that was reported by Markku Saloheimo, Ph.D., Senior Principal Scientist at VTT, during the PEGS Europe (Protein & Antibody Engineering Summit) in November 2019," said Anne Huuskonen, VTT Senior Scientist.

  • ACCESSWIRE

    Dyadic to Present at Two Upcoming Conferences

    Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins.

  • ACCESSWIRE

    Dyadic to Interview with Bloomberg TV on Friday, January 31, 2020

    JUPITER, FL / ACCESSWIRE / January 31, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying ...

  • Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports
    MarketWatch

    Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports

    A nearly weeklong rally for vaccine and diagnostics developers looking to capitalize on the coronavirus outbreak ended on Tuesday.

  • ACCESSWIRE

    Dyadic Interviewed with FOX Business Network

    JUPITER, FL / ACCESSWIRE / January 28, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb, was interviewed by Liz Claman "The Claman Countdown" from FOX Business Network on Monday, January 27, 2020. Liz Claman joined FOX Business Network (FBN) as an anchor in October 2007.

  • CDC officials say coronavirus is similar to SARS, no new U.S. cases reported
    MarketWatch

    CDC officials say coronavirus is similar to SARS, no new U.S. cases reported

    At least 110 people in 26 states have been identified as persons under investigation for coronavirus, Centers for Disease Control and Prevention officials said Monday.

  • ACCESSWIRE

    Dyadic to Interview with FOX Business Network on Monday, January 27, 2020

    JUPITER, FL / ACCESSWIRE / January 27, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying ...

  • DYAI: Dyadic’s Fourth Quarter Operational Update
    Zacks Small Cap Research

    DYAI: Dyadic’s Fourth Quarter Operational Update

    By John Vandermosten, CFA NASDAQ:DYAI In a press release issued earlier this week Dyadic International Inc. (NASDAQ:DYAI) provided an update on achievements during the fourth quarter 2019. The summary was provided prior to meetings and presentations at conferences over the next week. Dyadic announced yet another agreement with a big pharma company which will be the second top 10 pharma partner

  • ACCESSWIRE

    Dyadic Reports Continued Positive Business Trends and Scientific Results in Fourth Quarter 2019

    JUPITER, FL / ACCESSWIRE / January 6, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today provided an update on its recent business developments and scientific results in the fourth quarter of 2019.

  • Is Dyadic International, Inc. (NASDAQ:DYAI) Excessively Paying Its CEO?
    Simply Wall St.

    Is Dyadic International, Inc. (NASDAQ:DYAI) Excessively Paying Its CEO?

    In 2004 Mark Emalfarb was appointed CEO of Dyadic International, Inc. (NASDAQ:DYAI). First, this article will compare...

  • DYAI: Glycosylation Milestone Opens Doors For mAb Production
    Zacks Small Cap Research

    DYAI: Glycosylation Milestone Opens Doors For mAb Production

    By John Vandermosten, CFA NASDAQ::DYAI Dyadic (NASDAQ:DYAI) achieved an impressive milestone in its glycoengineering efforts which was announced via VTT’s 1 presentation at the Protein and Antibody Engineering Summit (PEGS) Europe in Lisbon a few weeks ago. The event was memorialized in a press release on November 25th. It announced that Dyadic’s filamentous fungi expression system Myceliophthora

  • Is Dyadic International, Inc. (DYAI) A Good Stock To Buy?
    Insider Monkey

    Is Dyadic International, Inc. (DYAI) A Good Stock To Buy?

    Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock. Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018. This means hedge funds […]

  • ACCESSWIRE

    Dyadic Announces Achieving Human Like Glycan Structures From Its Engineered C1 Cell Line

    JUPITER, FL / ACCESSWIRE / November 25, 2019 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, announced that data presented at the annual PEGS Europe Protein & Antibody Engineering Summit demonstrated that its C1 strain has been successfully glyco-engineered to impart the core human like G0 glycan structure at high levels. The G0 glycosylation data was presented by Markku Saloheimo, Ph.D., from the VTT Technical Research Centre of Finland Ltd ("VTT") at the conference in Lisbon, Portugal on Thursday, November 21.

  • DYAI: Third Quarter 2019 Financial & Operational Results
    Zacks Small Cap Research

    DYAI: Third Quarter 2019 Financial & Operational Results

    By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) released third quarter 2019 financial and operational results on November 13, 2019. Revenues were $0.5 million and represented research and development proceeds from partners working to develop C1. Total expenses were $2.4 million and net loss was ($1.7) million after adding interest

  • ACCESSWIRE

    Dyadic Reports Third Quarter 2019 Results And Recent Developments

    New Fully Funded Research Collaboration with Leading Animal Health Company; Fifth Partnership in Animal Sector Expansion of Existing Research Collaboration to Express an Additional Protein with Major Animal ...

  • We Think Dyadic International (NASDAQ:DYAI) Can Easily Afford To Drive Business Growth
    Simply Wall St.

    We Think Dyadic International (NASDAQ:DYAI) Can Easily Afford To Drive Business Growth

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • ACCESSWIRE

    Dyadic to Report Third Quarter 2019 Financial Results on Wednesday November 13, 2019

    JUPITER, FL / ACCESSWIRE / October 30, 2019 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to help accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, today announced that it will report its financial results for the quarter ended September 30, 2019 after the market close on Wednesday, November 13, 2019 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins.

  • ACCESSWIRE

    Dyadic Announces New Collaboration with Leading Animal Health Company

    JUPITER, FL / ACCESSWIRE / October 28, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global platform biotechnology company, announced today that it has entered into a fully funded collaboration with one of the leading animal health companies to demonstrate the C1 technology for expression and production of therapeutic proteins for companion and farm animal health diseases. Under the terms of the agreement, Dyadic will apply its proprietary and patented C1 gene expression platform to express three different types of proteins to be evaluated by our collaborator for its potential use in their research and commercial projects. There is a growing market demand among animal health companies to find a faster and more efficient gene expression technology platform.

  • ACCESSWIRE

    MicroCap Rodeo Investor Conference Lineup for October 15 and 16 - 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...